REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Protocols
13

Detailed Ipamorelin Cycle Log

Kai Crane·about 2 months ago
Logging my Ipamorelin cycle in detail for anyone who wants a real-world reference point. I am a 38-year-old male, train 4x per week, and my primary goal is recovery optimization. Week 1-2: Loading phase at conservative dosing. No noticeable effects, no side effects. Focused on getting injection technique and timing dialed in. Week 3-4: Moved to standard dosing. First signs of improvement in recovery metrics. My HRV started trending upward and sleep scores improved by about 10 percent on average. Week 5-6: Continuing standard dose. Recovery between training sessions is noticeably better. I can handle higher training volume without the accumulated fatigue I usually experience. Morning stiffness that I had been dealing with for years has decreased significantly. Week 7-8: Steady state. Benefits seem to have plateaued in a good way — consistent improvements without further escalation. This is where I feel the protocol has really settled in. I store reconstituted vials at 4C and use each within 28 days. Rotation between abdomen and deltoid injection sites every other day.

Comments (4)

Rue HeathDEMO·about 2 months ago

Great write-up. I have been running a similar Ipamorelin protocol and my experience aligns pretty closely with what you described. The sleep improvements were the first thing I noticed too, usually around week 2-3. One thing I would add is that I found keeping injection sites consistent with rotation between 4-5 spots worked better than random placement. Less irritation overall.

4
Nico JarvisDEMO·about 2 months ago

This matches my experience with Ipamorelin almost exactly. The timeline you describe — subtle at first, then clearly noticeable by week 4-5 — is very typical from what I have seen across multiple reports. For anyone reading this and feeling impatient in the first couple weeks, stick with it. The effects are cumulative and take time to establish.

5
True JimenezDEMO·about 2 months ago

Appreciate the honest assessment. Too many Ipamorelin reviews read like advertisements. The moderate but meaningful improvement you describe is exactly what I experienced as well. I think the community benefits more from realistic reports like this than from overhyped claims.

6
Hawk ChoDEMO·about 2 months ago

Question for you: did you get bloodwork done before and during your Ipamorelin protocol? I am about to start and trying to decide which panels to run. Obviously the basics but curious if there are any specific markers that are particularly informative for tracking Ipamorelin response.

2

Sign in to comment.